MedicaidCoverageMedium impact

Coverage of Brixadi for Opioid Use Disorders

Q: Who is affected by this change?

This affects Maryland Medicaid Psychiatry, Family Medicine, Internal Medicine, Pain Management providers in MD on Medicaid plans.

Maryland Medicaid·MD · Psychiatry, Family Medicine, Internal Medicine +1 more·Behavioral Health Administration Services Organization

Effective date

Not stated

We identified it

Jun 20, 2026

Days to comply

—

Summary

Maryland Medicaid now covers Brixadi (buprenorphine extended-release injection) for treatment of opioid use disorders. This expands medication-assisted treatment options for Medicaid patients with opioid addiction.

Action Required

Action needed

Immediately: Billing team should review the full policy document at the provided URL to identify specific HCPCS codes for Brixadi, prior authorization requirements, and billing procedures. Update billing system to include new coverage for Maryland Medicaid patients receiving Brixadi for opioid use disorder treatment.

Related policy hubs

Maryland Medicaid policies MD policy changes Psychiatry Family Medicine Internal Medicine Pain Management